Iris Reina Pérez

Ms. Iris Reina Pérez

University of Granada, Granada, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MFMariana F. Fernández
Mariana F. Fernández
Iris Reina PérezIris Reina Pérez
Iris Reina Pérez
JAJuan Manuel Astorga
Juan Manuel Astorga
ARAndrea Rodriguez-Carrillo
Andrea Rodriguez-Carrillo
Julio Plaza-DíazJulio Plaza-Díaz
Julio Plaza-Díaz
Luis FontanaLuis Fontana
Luis Fontana
The microorganisms that live symbiotically in human beings are increasingly recognized as important players in health and disease. The largest collection of these microorganisms is found in the gastrointestinal tract. Microbial composition reflects both genetic and lifestyle variables of the host. This microbiota is in a dynamic balance with the host, exerting local and distant effects. Microbial perturbation (dysbiosis) could contribute to the risk of developing health problems. Various bacterial genes capable of producing estrogen-metabolizing enzymes have been identified. Accordingly, gut microbiota is capable of modulating estrogen serum levels. Conversely, estrogen-like compounds may promote the proliferation of certain species of bacteria. Therefore, a crosstalk between microbiota and both endogenous hormones and estrogen-like compounds might synergize to provide protection from disease but also to increase the risk of developing hormone-related diseases. Recent research suggests that the microbiota of women with breast cancer differs from that of healthy women, indicating that certain bacteria may be associated with cancer development and with different responses to therapy. In this review, we discuss recent knowledge about the microbiome and breast cancer, identifying specific characteristics of the human microbiome that may serve to develop novel approaches for risk assessment, prevention and treatment for this disease.

24 May 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Julio Plaza-DíazJulio Plaza-Díaz
Julio Plaza-Díaz
AÁAna Isabel Álvarez-Mercado
Ana Isabel Álvarez-Mercado
CRCarmen M Ruiz-Marín
Carmen M Ruiz-Marín
Iris Reina PérezIris Reina Pérez
Iris Reina Pérez
APAlejandro J Perez-Alonso
Alejandro J Perez-Alonso
Luis FontanaLuis Fontana
Luis Fontana
Breast cancer ranks first in women, and is the second cause of death in this gender. In addition to genetics, the environment contributes to the development of the disease, although the factors involved are not well known. Among the latter is the influence of microorganisms and, therefore, attention is recently being paid to the mammary microbiota. We hypothesize that the risk of breast cancer could be associated with the composition and functionality of the mammary/gut microbiota, and that exposure to environmental contaminants (endocrine disruptors, EDCs) might contribute to alter these microbiota. We describe a case-control clinical study that will be performed in women between 25 and 70 years of age. Cases will be women diagnosed and surgically intervened of breast cancer (stages I and II). Women with antecedents of cancer or advanced tumor stage (metastasis), or who have received antibiotic treatment within a period of 3 months prior to recruitment, or any neoadjuvant therapy, will be excluded. Controls will be women surgically intervened of breast augmentation or reduction. Women with oncological, gynecological or endocrine history, and those who have received antibiotic treatment within a period of 3 months prior to recruitment will also be excluded. Blood, urine, breast tissue and stool samples will be collected. Data regarding anthropometric, sociodemographic, reproductive history, tumor features and dietary habits will be gathered. Metabolomic studies will be carried out in stool and breast tissue samples. Metagenomic studies will also be performed in stool and breast tissue samples to ascertain the viral, fungal, bacterial and archaea populations of the microbiota. Quantitation of estrogens, estrogen metabolites and EDCs in samples of serum, urine and breast tissue will also be performed. This is the first time that the contribution of bacteria, archaea, viruses and fungi together with their alteration by environmental contaminants to the risk of breast cancer will be evaluated in the same study. Results obtained could contribute to elucidate risk factors, improve the prognosis, as well as to propose novel intervention studies in this disease. ClinicalTrials.gov NCT03885648 , 03/25/2019. Retrospectively registered.

20 July 2022 in Environmental Research
Verified
Journal Article
Open access
HAHelle Raun Andersen
Helle Raun Andersen
ADArthur David
Arthur David
CFCarmen Freire
Carmen Freire
MFMariana F. Fernández
Mariana F. Fernández
SDShereen Cynthia D'CRuz
Shereen Cynthia D'CRuz
LBLudek Blaha
Ludek Blaha
Pyrethroid metabolites are widely detectable in urine from the general population, including pregnant women and children. Pyrethroids are neurotoxic and suggested endocrine disruptors. Exposure during vulnerable developmental time windows may have long-term impacts on neurodevelopment. To evaluate the epidemiological evidence for neurodevelopmental effects related to prenatal and childhood pyrethroid exposure in a systematic review and to assess biological plausibility by evaluating mechanistic evidence. We searched PubMed and Web of Science up to September 1, 2021 and included original studies published in English in which pyrethroid exposure was measured or estimated during pregnancy or childhood and associations with neurodevelopmental outcomes in the children were investigated. The Navigation Guide Systematic Review Methodology was used to evaluate the epidemiological evidence. For mechanistic evidence, we focused on relevant key events (KEs) suggested in Adverse Outcome Pathways (AOPs) using the OECD-supported AOP-wiki platform. A systematic search combining the KEs with pyrethroids, including 26 individual compounds, was performed in the ToxCast database. Twenty-five epidemiological studies met the inclusion criteria, 17 presented findings on prenatal exposure, 10 on childhood exposure and two on both exposure windows. The overall body of evidence was rated as "moderate quality" with "sufficient evidence" for an association between prenatal pyrethroid exposure and adverse neurodevelopment. For childhood exposure, the overall rating was "low quality" with "limited evidence" because of cross-sectional study design. Regarding mechanistic evidence, we found that pyrethroids are able to interfere with neurodevelopmental KEs included in established AOPs for adverse neurodevelopmental. The evidence was strongest for interference with thyroid hormone (TH) function. Pyrethroids are probably human developmental neurotoxicants and adverse impacts of pyrethroid exposure on neurodevelopment are likely at exposure levels occurring in the general population. Preventive measures to reduce exposure among pregnant women and children are warranted.

1 June 2021 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
Iris Reina PérezIris Reina Pérez
Iris Reina Pérez
AOAlicia Olivas-Martinez
Alicia Olivas-Martinez
Vicente MustielesVicente Mustieles
Vicente Mustieles
FRFrancisco Javier Ruiz-Ojeda
Francisco Javier Ruiz-Ojeda
JMJosé Manuel Molina-Molina
José Manuel Molina-Molina
MFMariana F. Fernández
Mariana F. Fernández

1 July 2021 in Chemosphere
Verified
Journal Article
Closed access
MFM.F. Fernández
M.F. Fernández
Vicente MustielesVicente Mustieles
Vicente Mustieles
BSB. Suárez
B. Suárez
Iris Reina PérezIris Reina Pérez
Iris Reina Pérez
AOAlicia Olivas-Martinez
Alicia Olivas-Martinez
FVFernando Vela-Soria
Fernando Vela-Soria

1 January 2022 in Science of The Total Environment
Verified
Journal Article
Open access
Vicente MustielesVicente Mustieles
Vicente Mustieles
ARAndrea Rodríguez-Carrillo
Andrea Rodríguez-Carrillo
FVFernando Vela-Soria
Fernando Vela-Soria
SDShereen Cynthia D'CRuz
Shereen Cynthia D'CRuz
ADArthur David
Arthur David
MFMariana F. Fernández
Mariana F. Fernández
Bisphenol A (BPA) exposure has been linked to altered behavior in children. Within the European Human Biomonitoring Initiative (HBM4EU), an adverse outcome pathway (AOP) network was constructed supporting the mechanistic link between BPA exposure and brain-derived neurotrophic factor (BDNF). To test this toxicologically-based hypothesis in the prospective INMA-Granada birth cohort (Spain). BPA concentrations were quantified by LC-MS/MS in spot urine samples from boys aged 9-11 years, normalized by creatinine and log-2 transformed. At adolescence (15-17 years), blood and urine specimens were collected, and serum and urinary BDNF protein levels were measured using immunoassays. DNA methylation levels at 6 CpGs in Exon IV of the BDNF gene were also assessed in peripheral blood using bisulfite-pyrosequencing. Adolescent's behavior was parent-rated using the Child Behavior Checklist (CBCL/6-18) in 148 boys. Adjusted linear regression and mediation models were fit. Childhood urinary BPA concentrations were longitudinally and positively associated with thought problems (β = 0.76; 95% CI: 0.02, 1.49) and somatic complaints (β = 0.80; 95% CI: -0.16, 1.75) at adolescence. BPA concentrations were positively associated with BDNF DNA methylation at CpG6 (β = 0.21; 95% CI: 0.06, 0.36) and mean CpG methylation (β = 0.10; 95% CI: 0.01, 0.18), but not with total serum or urinary BDNF protein levels. When independent variables were categorized in tertiles, positive dose-response associations were observed between BPA-thought problems (p-trend = 0.08), BPA-CpG6 (p-trend ≤ 0.01), and CpG6-thought problems (p-trend ≤ 0.01). A significant mediated effect by CpG6 DNA methylation was observed (β = 0.23; 95% CI: 0.01, 0.57), accounting for up to 34% of the BPA-thought problems association. In line with toxicological studies, BPA exposure was longitudinally associated with increased BDNF DNA methylation, supporting the biological plausibility of BPA-behavior relationships previously described in the epidemiological literature. Given its novelty and preliminary nature, this effect biomarker approach should be replicated in larger birth cohorts.